01—Abstract
Summary
Summary of the 8-K filed October 29, 2025. Cited figures are marked; the original filing is the authoritative source.
Centene reported third-quarter 2025 results that were dominated by a non-cash goodwill impairment.
GAAP diluted loss per share was $(13.50), driven by a $6.7 billiona goodwill impairment, while adjusted diluted EPS was $0.50. Excluding the impairment and other items, adjusted net earnings were $245 million, down sharply from $849 million a year earlier. The company cited the One Big Beautiful Bill Act and a decline in its stock price as triggers for the July quantitative impairment test.
Post-impairment, debt-to-capital rose to 45.5% from 39.1% a year earlier, and stockholders' equity fell to $21.0 billionb from $26.5 billion at year-end 2024. Operationally, premium and service revenues grew 22% to $44.9 billion, led by Medicare PDP (up 66%) and Commercial/Marketplace (up 26%). However, the health benefits ratio deteriorated to 92.7% from 89.2%, reflecting higher Marketplace medical costs, lower Marketplace risk adjustment revenue, and IRA-related PDP program changes.
Medicaid HBR was 93.4%, and that figure included a roughly 40 basis point benefit from a retroactive revenue adjustment. Commercial HBR rose to 89.9% from 80.0%. The SG&A ratio improved to 7.0% from 8.3%, and Q3 operating cash flow was $1.4 billionc.
Management raised its full-year 2025 adjusted diluted EPS forecast by $0.25d to at least $2.00, while the GAAP loss per share outlook is no worse than $(12.85). Investors should weigh the improved adjusted outlook against the sharply higher medical cost ratios, the leverage increase, and the fact that the Q3 adjusted tax rate of 2.5% flattered EPS by about $0.10 per share.
02—Key points
Key Highlights
- GAAP diluted loss of $(13.50) per share, driven by a $6.7 billion non-cash goodwill impairment; adjusted diluted EPS of $0.50 versus $1.62 in Q3 2024.
- Full-year 2025 adjusted diluted EPS guidance raised to at least $2.00 (from $1.75); GAAP loss per share guided to no worse than $(12.85).
- Health benefits ratio rose to 92.7% from 89.2%, with Commercial HBR at 89.9% (vs. 80.0%) and Medicare HBR at 94.3% (vs. 88.0%); Medicaid HBR was 93.4%, including a ~40 bp retroactive benefit.
- Premium and service revenues grew 22% to $44.9 billion, driven by Medicare PDP (+66%), Commercial (+26%), and Medicaid rate increases (+9%).
- Debt-to-capitalization increased to 45.5% from 39.1% after the impairment reduced equity; total debt was $17.6 billion with the $4.0 billion revolver undrawn.
- Adjusted SG&A ratio improved to 7.0% from 8.3%, reflecting expense leverage and PDP growth.
- Q3 adjusted effective tax rate of 2.5% contributed roughly $0.10 to adjusted EPS, versus an expected full-year rate of 20-21%.
03—Questions
Frequently Asked Questions
Why did Centene record a loss this quarter?
The GAAP loss was driven by a $6.7 billion non-cash goodwill impairment, recorded after a quantitative test prompted by July 2025 market conditions, including the One Big Beautiful Bill Act and the decline in the company's stock price. The impairment is excluded from adjusted EPS, but it reduced retained earnings and stockholders' equity and raised leverage.
Did Centene's core profitability improve?
Not on a margin basis. The health benefits ratio rose 350 basis points to 92.7%, mainly from Marketplace medical costs, weaker Marketplace risk adjustment, PDP changes under the Inflation Reduction Act, and higher Medicaid behavioral health and home health costs. Adjusted net earnings fell to $245 million from $849 million, although the SG&A ratio improved.
How much of the adjusted EPS came from one-time or favorable items?
The release says the low adjusted effective tax rate in Q3 (2.5% versus an expected full-year 20-21%) contributed about $0.10 per share. The Medicaid HBR also included a roughly 40 basis point benefit from a retroactive revenue adjustment for Q1 and Q2 2025. Investors should consider both when assessing run-rate earnings.
What does the raised guidance imply?
The full-year adjusted diluted EPS forecast is at least $2.00, up $0.25 from $1.75. Nine-month adjusted EPS was $3.26, so guidance implies a fourth-quarter adjusted loss or near-breakeven result, a sizable step down from the year-to-date run rate. Management attributed the raise to the quarter's results and near-term milestones it laid out in July.
How is Centene's balance sheet and liquidity position?
Cash, investments and restricted deposits totaled $38.8 billion, with $37.6 billion in regulated entities. Days in claims payable were 48, up one day from Q2 but down from 51 a year earlier. Total debt was $17.6 billion, and the $4.0 billion revolving credit facility had no borrowings. Q3 operating cash flow was $1.4 billion, and nine-month operating cash flow was $4.7 billion.
04—Continue